4D Molecular Therapeutics (FDMT) EBT Margin: 2020-2025
Historic EBT Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -63,172.22%.
- 4D Molecular Therapeutics' EBT Margin rose 139822778.00% to -63,172.22% in Q3 2025 from the same period last year, while for Sep 2025 it was -174,284.17%, marking a year-over-year increase of 66932172.00%. This contributed to the annual value of -434,570.27% for FY2024, which is 43408455.00% down from last year.
- 4D Molecular Therapeutics' EBT Margin amounted to -63,172.22% in Q3 2025, which was up 82.64% from -363,980.00% recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' EBT Margin registered a high of 169,852.63% during Q4 2023, and its lowest value of -4,965,000.00% during Q4 2024.
- For the 3-year period, 4D Molecular Therapeutics' EBT Margin averaged around -714,794.62%, with its median value being -115,682.14% (2024).
- In the last 5 years, 4D Molecular Therapeutics' EBT Margin slumped by 513,485,263bps in 2024 and then skyrocketed by 139,822,778bps in 2025.
- Over the past 5 years, 4D Molecular Therapeutics' EBT Margin (Quarterly) stood at -27,256.52% in 2021, then spiked by 2,506,069bps to -2,195.83% in 2022, then skyrocketed by 17,204,846bps to 169,852.63% in 2023, then slumped by 513,485,263bps to -4,965,000.00% in 2024, then skyrocketed by 139,822,778bps to -63,172.22% in 2025.
- Its last three reported values are -63,172.22% in Q3 2025, -363,980.00% for Q2 2025, and -343,135.71% during Q1 2025.